BioPharmSignal logoBioPharmSignal

Biotech News

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics (MGNX)MacroGenicsCompany update

ROCKVILLE, MD, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management team will participate in the

Related news

MGNXMacroGenics2026-11-03 21:05 EST

MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors

MGNXMacroGenics2026-10-26 11:06 EST

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

STROSutro Biopharma2026-11-04 13:00 EST

Sutro Biopharma to Participate in Upcoming Investor Conferences

RLAYRelay Therapeutics2026-11-02 21:05 EST

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

ANGOAngioDynamics2026-10-29 12:00 EST

AngioDynamics to Participate in Upcoming Investor Conferences

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

RVMDRevolution Medicines2026-10-27 20:05 EST

Revolution Medicines to Participate in November 2026 Investor Conferences

FATEFate Therapeutics2026-10-01 11:00 EST

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

IDYAIDEAYA Biosciences2026-11-04 11:00 EST

IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

View all latest news

MacroGenics

Antibody Engineering Company MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates. ADC Portfolio MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid...

Recent company news

MGNXMacroGenics2026-11-05 21:05 EST

MacroGenics to Participate in Upcoming Investor Conferences

MGNXMacroGenics2026-11-03 21:05 EST

MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors

MGNXMacroGenics2026-10-26 11:06 EST

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

MGNXMacroGenics2026-10-23 13:15 EST

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN

MGNXMacroGenics2026-10-15 20:05 EST

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

Stock data

Close
2.22 USD
Market cap
257.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States